Bluebird Bio To Present Additional Long-Term Follow-up Data From Gene Therapy Programs In Sickle Cell Disease And Beta-Thalassemia At The 66th ASH Annual Meeting and Exposition

bluebird bio将在第66届ASH年会上发布有关镰状细胞病和β-地中海贫血基因治疗计划的额外长期随访数据

Benzinga · 2024/11/05 22:19

bluebird bio, Inc. (NASDAQ:BLUE) today announced that new and updated data from its lentiviral vector (LVV) gene addition programs in patients with sickle cell disease who have a history of vaso-occlusive events and patients with beta-thalassemia who require regular blood transfusions will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will take place December 7-10, 2024 at the San Diego Convention Center and online.

美国公司bluebird bio，Inc.（纳斯达克：BLUE）今日宣布，将在第66届美国血液学会（ASH）年会和博览会上发布其镶嵌病毒载体（LVV）基因增加计划在患有疼痛性血细胞病史和需要定期输血的β地中海贫血患者中的新数据和更新数据。会议将于2024年12月7日至10日在圣迭戈会议中心和在线上举行。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Bluebird Bio To Present Additional Long-Term Follow-up Data From Gene Therapy Programs In Sickle Cell Disease And Beta-Thalassemia At The 66th ASH Annual Meeting and Exposition

Bluebird Bio To Present Additional Long-Term Follow-up Data From Gene Therapy Programs In Sickle Cell Disease And Beta-Thalassemia At The 66th ASH Annual Meeting and Exposition

风险及免责提示

声明